Former U.S. Sen. Ben Sasse is reporting significant progress in his battle with stage 4 metastatic pancreatic cancer. Diagnosed with the aggressive disease that had spread to his liver and lungs, Sasse was initially given a grim prognosis of three to four months to live.
He entered a clinical trial for an experimental oral therapy named daraxonrasib. This drug is designed to target and block a defective gene, RAS, that fuels uncontrolled cancer cell growth. Sasse shared in a recent interview that he has experienced a "massive 76% reduction in tumor volume" over the past four months and significantly less pain.
Clinical trial data for daraxonrasib in patients with metastatic pancreatic cancer, who did not respond to standard chemotherapy, shows a median survival of 13 months compared to approximately six months for those continuing chemotherapy. Experts note this targeted therapy represents a potential step-change for a disease with historically slow progress.
Daraxonrasib works by inhibiting the RAS pathway, which is hyperactive in most pancreatic tumors. While the drug is still in late-stage clinical trials and not yet FDA-approved, its early results, including doubling survival rates in some patient groups, offer new hope for personalized treatment strategies. Common side effects reported include rash, diarrhea, and fatigue, generally manageable with dose adjustments or supportive medications.